Product information 

Ready to use, synthetic and free of any animal-origin component 


Lentiviral vectors (LV) manufacturing using HEK-293 derivative cells cultivated in suspension

Number of transfections 

100 mL of FectoVIR®-LV transfection reagent is sufficient to transfect on average 50 L of cell culture (using standard conditions)

Storage condition 

Store FectoVIR®-LV at 5 °C ± 3°C. 
Expiry date is indicated in the certificate of analysis and on the product. 

Product documentation 

Certificate of Analysis 
Certificate of origin 
Non-hazardous product statement 


Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs. 

Discover Polyplus’ complementary DOE service to fast-track optimization of lentivirus production with FectoVIR®-LV. 

Ordering Information

Reference NumberProductAmount of reagent
101000187FectoVIR®-LV FectoVIR®-LV 1 mL
101000188FectoVIR®-LV FectoVIR®-LV 10 mL
101000189FectoVIR®-LV FectoVIR®-LV 100 mL

Want to request a quote

Get Now


Improve lentiviral vector productivity using FectoVIR®-LV

The production of lentiviral vectors for cell and gene therapy is performed using 3rd generation plasmid systems in HEK-293 and derivative cell systems. Transfection reagents are considered as a critical raw material because of its major impact on  productivity. Choosing the transfection reagent based on the best titers is a must for process economics and intensification. FectoVIR®-LV increases up to 3-fold functional titers in comparison to other commercially available lentivirus-specific transfection reagents.

Reduce lentiviral vector manufacturing costs using DOE approach

Improving titers is one of the key parameters to increase number of doses per batch and reduce cost per dose. When combined with reduced .consumption of additional critical raw material such as DNA quantity, overall manufacturing costs can be further reduced. FectoVIR®-LV both allows gain in productivity while reducing by 2-fold DNA consumption. To support our customers, Polyplus offers a comprehensive DOE service to optimize key parameters of transfection step to reach higher titers.

Increase your scale without being limited by the transfection mix

Transient transfection at large scale comes with challenges, of which transfer of transfection mix within an optimal trimeframe. This step can be a limit if the transfection reagent is not adapted for large scale manufacturing. FectoVIR®-LV has been designed to increase complex stability and decrease complex volume allowing sufficient time to transfer the mix into large bioreactors (>200 L). FectoVIR®-LV has proven its efficiency using the recommended 5% complexation volume and 30 min of complexation volume, which can be even further optimized to fit your process. Polyplus recommends performing a DOE study adapted to your system.

All Data

We power your process with fast process optimization

Manufacturing lentiviral vectors for therapeutic treatments (ex. vivo gene therapy and cell therapy) requires the right set of tools.  

Find the Information you need

Get in depth coverage on how to accelerate your process optimization : Link to DOE page

Direct benefits of DOE on lentiviral vector manufacturing 

Case study: CDMO manufacturing optimization process

Looking for a Product Protocol or Certificate of Analysis

Create an Account

Other sources to help you understand FectoVIR®-LV better

Other Sources

Check our FAQs

These FAQs are organized by application to guide you to find the best answer possible.

Product Documents

You have access to all the documents related to the transfection reagent.

Polyplus Database

Search for publications in our Transfection Database with Polyplus transfection reagents


This lexicon will help you to understand the different terms related to Polyplus-transfection®.

Learn more



Accelerating Lentiviral Vector Manufacturing with Well-aligned Plasmid and Vector Manufacturing Platforms
Easy – Lentiviral pTransgene
Improving AAV Manufacturing Process with Design of Experiment and Fit for Purpose transfection Reagent


Webinar Replay : Accelerating lentivirus manufacturing: choosing the right plasmid manufacturing platform
Optimization of lentiviral vector production from early stages to GMP
Simplify manufacturing scale-up of therapeutic viral vectors


Overview of CAR-T Cell Generation Using Optimized Plasmid Design and Lentiviral Vector Production
Poster : Next generation transfection reagent for large scale therapeutic lentiviral vector production
FectoVIR®-LV : Ready to use, synthetic and free of any animal-origin component 

View All Resources